Potential role of intravitreal human placental stem cell implants in inhibiting progression of diabetic retinopathy in type 2 diabetes: Neuroprotective growth factors in the vitreous

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 691-696

  Scalinci, Sergio Zaccaria ^a,b   Scorolli, Lucia ^a,b   Corradetti, Giulia ^a,b   Domanico, Daniela ^c   Vingolo, Enzo Maria ^d   Meduri, Alessandro ^e   Bifani, Mario ^f   Siravo, Duilio ^g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SANTA MARIA GORETTI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g US Army health Clinic   (Italy)

Author keywords

Apoptosis mechanism; Chemically induced diabetes mellitus; Diabetic retinopathy; Neuroprotection; Stem cells

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; VITREOUS BODY;

EID: 79958856351     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S21161     Document Type: Article

References (21)

1. Joe AW, Gregory-Evans K. Mesenchymal stem cells and potential applications in treating ocular disease. Curr Eye Res. 2010;35(11): 941-952.
2. Jeganathan VS, Palanisamy M. Treatment viability of stem cells in ophthalmology. Curr Opin Ophthalmol. 2010;21(3):213-217.
3. Tsagias N, Koliakos I, Lappa M, et al. Placenta perfusion has hematopoi-etic and mesenchymal progenitor stem cell potential. Transfusion. March 7, 2011. [Epub ahead of print].
4. Parolini O, Caruso M. Preclinical studies on placenta-derived cells and amniotic membrane: An update. Placenta. 2011;32(Suppl 2): S186-S195.
5. Abdulrazzak H, Moschidou D, Jones G, et al. Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface. 2010;7(Suppl 6):S689-S706.
6. Marongiu F, Gramignoli R, Sun Q, et al. Isolation of amniotic mesen-chymal stem cells. Curr Protoc Stem Cell Biol. 2010;Chapter 1: Unit 1E.5.
7. Menier C, Rouas-Freiss N, Favier B, et al. Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens. 2010;75(3):201-206.
8. Volarevic V, Arsenijevic N, Lukic ML, et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells. 2011;29(1):5-10.
9. Remuzzi A, Cornolti R, Bianchi R, et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia. 2009;52(12): 2653-2661.
10. Daly M. Sugars, insulin sensitivity, and the postprandial state. Am J Clin Nutr. 2003;78(4):865S-872S.
11. Lee JH, Yang SH, Oh JM, et al. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: Comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol. 2010;62(1):1-23.
12. Liu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol. February 16, 2011. [Epub ahead of print].
13. Inberg A, Linial M. Protection of pancreatic beta-cells from various stress conditions is mediated by DJ-1. J Biol Chem. 2010;285(33): 25686-25698.
14. Dunnett SB, Torres EM, Richards H, et al. Effects of surgical anaesthesia on the viability of nigral grafts in the rat striatum. Cell Transplant. 1998;7(6):567-572.
15. Aloe L, Rossi S, Manni L. Altered expression of nerve growth factor and its receptors in the kidneys of diabetic rats. J Nephrol. March 4, 2011. [Epub ahead of print].
16. Mahdy RA, Nada WM, Hadhoud KM, et al. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye (Lond). 2010;24(10):1576-1584.
17. Liu X, Li Y, Liu Y, et al. Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy. Am J Pathol. 2010;176(1): 504-515.
18. Talahalli A, Zarini S, Sheibani N, et al. Increased synthesis of leukot-rienes in the mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(3):1699-1708.
19. Couri CE, Voltarelli JC. Stem cell therapy for type 1 diabetes mellitus: A review of recent clinical trials. Diabetol Metab Syndr. 2009; 1(1):19.
20. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6): 1134-1146.
21. Bandello F, Blumenkranz MS, Jiao J, et al. 12-Month evaluation of dexamethasone intravitreal implant in patients with macular edema due to central retinal vein occlusion. Abstr 6397. Association for Research in Vision and Ophthalmology annual meeting, May 2-6 2010, Fort Lauderdale, FL.